WilliamEyreLawlerMD

Oncology • Fullerton, CA

Physician

Join to view full profile

Dr. Lawler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lawler's full profile

Already have an account?

Office
2151 N Harbor Blvd
Suite 2200
Fullerton, CA 92835
Phone+1 714-446-5900

Fax+1 714-446-5800

Education & Training

Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 1970 - 1972
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1968 - 1970
University of ChicagoResidency, Internal Medicine, 1967 - 1968
Stanford University School of MedicineClass of 1967

Certifications & Licensure

CA State Medical License 1969 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
ACTIVE_NOT_RECRUITING
PHASE3
A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) Start of enrollment: 2013 Dec 13
Terminated
Phase 2
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
ACTIVE_NOT_RECRUITING
PHASE3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Trastuzumab Deruxtecan Alone or in Combination with Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer Start of enrollment: 2020 Oct 09
RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

30 citations
Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non–Small-Cell Lung C...
Heather A. Wakelee, Zanete Zvirbule, Filippo de Braud, C. Daniel Kingsley, Tarek Mekhail
Clinical Lung Cancer. 2017-01-01
32 citations
Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and cor...
Denise A. Yardley, Peter A. Kaufman, Weidong Huang, Lea Krekow, Michael Savin
Breast Cancer Research. 2015-03-18

Press Mentions

Durvalumab with or Without Tremelimumab vs Standard Chemotherapy in 1L Treatment of Metastatic NSCLCApril 13th, 2020